Cyberliver Announces Poster Presentation of AlcoChange
Pilot Study at The Liver Meeting 2018
Cyberliver reports a positive pilot study of AlcoChange, a patented Smartphone Tool and Behavioural Intervention Platform to Reduce Alcohol Consumption in Alcohol-Related Liver Disease. The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life.
London, United Kingdom, November 12, 2018 – Cyberliver Ltd., a developer of cutting edge solutions for liver care, today announced that Dr Gautam Mehta and team will present a poster at The Liver Meeting 2018 of the American Association for the Study of Liver Diseases held on Friday, November 9th through Tuesday, November 13th, at the Moscone North and South Convention Centre in San Francisco.
The poster is entitled: “AlcoChange: A Pilot Study of a Smartphone Tool to Reduce Alcohol Consumption in Alcohol-Related Liver Disease (Poster #1398)” will be presented on Sunday, November 11 2018, between 8:00 AM and 5:30 PM at Hall C – Poster Hall.
Dr. Gautam Mehta, Clinical Lead of the study, Consultant and Senior Lecturer in Hepatology at Royal Free Hospital said, “We are delighted to be presenting this study at The Liver Meeting 2018. The data demonstrate the potential of digital tools like AlcoChange to help manage alcohol-related liver disease (ARLD).” The AlcoChange clinical study, which ran from spring 2015 to end of 2017 at Royal Free London NHS Trust, supported by The Health Foundation and led by Prof. Kevin Moore and Dr. Gautam Mehta, clearly demonstrated that a smartphone app/breathalyzer can be used for self-monitoring and for Behavior Change Interventions (BCIs) in patients with ARLD, with a clear “dose response” amongst compliant patients. “Smartphone apps are a scalable intervention to help maintain abstinence in ARLD.”
Commenting on the study, Prof. Rajiv Jalan, Clinician Scientist, Prof. of Hepatology, Head of Liver Failure group at UCL said, “The data from this study is very exciting and shows that we can potentially find new treatments using digital technologies for treating liver disease to reduce deaths and improve quality of life.”
Cyberliver is a company that focuses on delivering cutting edge solutions for liver care via use of innovative technology, based out of London, England, UK.